Alvogen, Inc.
Alvogen, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 2009, the company has rapidly expanded its operations across key regions, including North America, Europe, and Asia. Alvogen focuses on developing and manufacturing generic and specialty pharmaceuticals, with a strong emphasis on high-quality, affordable medications. The company is recognised for its innovative approach to drug development, particularly in the areas of oncology, respiratory, and central nervous system therapies. Alvogen's commitment to quality and efficiency has positioned it as a competitive force in the market, achieving significant milestones such as the successful launch of numerous generic products. With a robust portfolio and a dedication to improving patient access to essential medicines, Alvogen continues to make strides in the pharmaceutical landscape.
DitchCarbon Score
How does Alvogen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alvogen, Inc.'s score of 19 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alvogen, Inc.'s reported carbon emissions
In 2022, Alvogen, Inc. reported total carbon emissions of approximately 721,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 721,000 kg CO2e. This included 573,000 kg CO2e from business travel and 145,000 kg CO2e from waste generated in operations. Scope 1 emissions were approximately 19,000 kg CO2e, while Scope 2 emissions totalled about 217,000 kg CO2e. In 2021, the company recorded total emissions of around 294,000 kg CO2e in Scope 3, with business travel contributing 207,000 kg CO2e. Scope 1 emissions were about 12,000 kg CO2e, and Scope 2 emissions reached approximately 206,000 kg CO2e. In 2020, Alvogen's emissions were approximately 261,000 kg CO2e for Scope 3, with business travel at 192,000 kg CO2e. Scope 1 emissions were about 16,000 kg CO2e, and Scope 2 emissions totalled around 202,000 kg CO2e. Despite these figures, Alvogen has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further clarity on their long-term climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 16,000 | 00,000 | 00,000 |
| Scope 2 | 202,000 | 000,000 | 000,000 |
| Scope 3 | 261,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alvogen, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
